Tamoxifen Use in Patients with Ductal Carcinoma In Situ and T1a/b N0 Invasive Carcinoma

1998, Tamoxifen for early breast cancer, Lancet, 351, 1451, 10.1016/S0140-6736(97)11423-4 Olivotto, 1997, Compliance with practice guidelines for node-negative breast cancer, J Clin Oncol, 15, 216, 10.1200/JCO.1997.15.1.216 Guadagnoli, 1998, The quality of care for treatment of early stage breast carcinoma. Is it consistent with national guidelines, Cancer, 83, 302, 10.1002/(SICI)1097-0142(19980715)83:2<302::AID-CNCR14>3.0.CO;2-X Ernster, 1996, Incidence of and treatment for ductal carcinoma in situ of the breast, JAMA, 275, 913, 10.1001/jama.275.12.913 Miller, 1993, Recent incidence trends for breast cancer in women and the relevance of early detection, CA Cancer J Clin, 43, 27, 10.3322/canjclin.43.1.27 Morrow, 2001, Who should not receive chemotherapy? Data from American databases and trials, J Natl Cancer Inst Monographs, 30, 109, 10.1093/oxfordjournals.jncimonographs.a003446 Fisher, 1998, Lumpectomy and radiation therapy for the treatment of intraductal breast cancer, J Clin Oncol, 16, 441, 10.1200/JCO.1998.16.2.441 Rosen, 1993, Factors influencing prognosis of 767 T1N0M0/T2N0M0 patients with long term follow-up, J Clin Oncol, 11, 2090, 10.1200/JCO.1993.11.11.2090 2001, National Institutes of Health Consensus Development Conference Statement, J Natl Cancer Inst, 93, 979, 10.1093/jnci/93.13.979 Goldhirsch, 2001, Meeting highlights, J Clin Oncol, 19, 3817, 10.1200/JCO.2001.19.18.3817 Goldhirsch, 2003, Meeting highlights, J Clin Oncol, 21, 1, 10.1200/JCO.2003.04.576 Fisher, 1998, Tamoxifen for prevention of breast cancer, J Natl Cancer Inst, 90, 1371, 10.1093/jnci/90.18.1371 Tchou, 2004, Acceptance of tamoxifen chemprevention by physicians and women at risk, Cancer, 100, 1800, 10.1002/cncr.20205 Yen, 2004, Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ, Cancer, 100, 942, 10.1002/cncr.20085 Swain, 2001, Tamoxifen for patients with estrogen receptor negative breast cancer, J Clin Oncol, 19, 935 Swain, 2004, Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer, J Natl Cancer Inst, 96, 516, 10.1093/jnci/djh097 Allred, 2002, Estrogen receptor expression as a predictive marker of effectiveness of tamoxifen in the treatment of DCIS, Br Ca Res Treat, 76, S36 Fisher, 1989, A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor positive tumors, N Engl J Med, 320, 479, 10.1056/NEJM198902233200802 Rakovitch, 2003, A comparison of risk preception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer, Breast Cancer Res Treat, 77, 285, 10.1023/A:1021853302033 DeMorgan, 2002, “Well, have I got cancer or haven’t I?” The psychological issues of women diagnosed with ductal carcinoma in situ, Health Expressions, 5, 310, 10.1046/j.1369-6513.2002.00199.x Mariotto, 2002, Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States 1975–1999, J Natl Cancer Inst, 94, 1626, 10.1093/jnci/94.21.1626 Harlan, 2002, Adjuvant therapy for breast cancer, J Clin Oncol, 20, 1809, 10.1200/JCO.2002.07.052 2002, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer, Lancet, 359, 2131, 10.1016/S0140-6736(02)09088-8 Healey, 1993, Contralateral breast cancer, J Clin Oncol, 11, 1545, 10.1200/JCO.1993.11.8.1545